Concepedia

Clayton D. Knox

CD

Statistics

Publications

14

Citations

562

H-Index

13

Active since

2003

Affiliations

Vanderbilt University Medical Center(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

The University of Texas MD Anderson Cancer Center

Institute of Cancer Research

Clayton D. Knox is an author at Vanderbilt University Medical Center specializing in life sciences, pharmacology, and mitochondrial biology.

Publications per year

2003–2018

14

Publications

14

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

Andrew J. Wagner, Udai Banerji, Amit Mahipal et al. · Journal of Clinical Oncology · 2017 · 125 citations

, , +17

2-APB protects against liver ischemia-reperfusion injury by reducing cellular and mitochondrial calcium uptake

Ian B. Nicoud, Clayton D. Knox, Christopher M. Jones et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2007 · 56 citations

, , +14

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik et al. · Leukemia Research · 2016 · 53 citations · Full text

, , +12

Mitochondrial P2Y‐Like receptors link cytosolic adenosine nucleotides to mitochondrial calcium uptake

Andrey E. Belous, Aya Wakata, Clayton D. Knox et al. · Journal of Cellular Biochemistry · 2004 · 51 citations

, , +10

Mitochondrial calcium transport is regulated by P2Y1- and P2Y2-like mitochondrial receptors

Andrey E. Belous, Christopher M. Jones, Aya Wakata et al. · Journal of Cellular Biochemistry · 2006 · 43 citations

, , +17

1–5 of 14